AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01439932 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: algometer
Description: Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.~The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people \[Andrew 1987\]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). \[Linda et al 2007\]
Study NCT04646668 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: E-cigarette and Heat not burn
Description: Current smokers will be randomized to session order and complete a standardized 10-puff bout (5 minutes) followed by a 60-minute ad libitum session with each product (usual brand cigarette, e-cigarette, heat-not-burn).
Study NCT01256424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL 5% with illumination
Description: Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
Study NCT01256424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL 1% with illumination
Description: Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
Study NCT01256424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAL 0.2% with illumination
Description: Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
Study NCT01256424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment without illumination
Description: Treatment with a singe dose of 2g placebo ointment, no photoactivation
Study NCT01737463 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic snare papillectomy
Description: Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
Study NCT01636102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza virus vaccine (TIV)
Description: A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
Study NCT00528125 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: active laser acupuncture
Description: low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
Study NCT00528125 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: placebo laser acupuncture
Description: placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib in mannitol high sweet
Description: bosutinib in mannitol high sweet
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib taste low flavour
Description: bosutinib solution low flavour
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib high flavour
Description: bosutinib solution high flavour
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules in applesauce
Description: Bosutinib capsules in applesauce
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsules in yogurt
Description: bosutinib capsules in yogurt
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules in water
Description: sham comparator, bosutinb in water retest
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib capsules in low sweet
Description: bosutinib capsules in low sweet
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules high sweet
Description: Bosutinib capsules high sweet
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules low flavour
Description: Bosutinib capsules low flavour
Study NCT01852565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darapladib
Description: Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
Study NCT01852565 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
Study NCT03301168 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BPX-501 T cells
Description: T cells transduced with CaspaCIDe® safety switch
Study NCT03301168 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: administered to inactivate BPX-501 cells in the event of GVHD
Study NCT04470648 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test for SARS-COV2 serology
Description: each person who will accept to participate will have a bood test for a SARS-COV2 serology
Study NCT02091856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Description: Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
Study NCT03541317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Strategy: REP
Description: Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; and ongoing technical assistance in CBT implementation.
Study NCT03190252 — intervention group
Intervention type: OTHER
Intervention: Exposure to oxygen partial pressure of 130 kPa
Description: Open sea diving to a maximum depth of 100 msw while breathing Trimix.
Study NCT03541317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 1 Strategy: REP + Coaching
Description: Schools will receive a daylong didactic training covering core elements of CBT and proper screening and identification of students; training to help SPs identify eligible students; a package that includes tools to deploy CBT; ongoing technical assistance in CBT implementation; and weekly visits from a CBT expert or Coach, for a minimum of 12 weeks.
Study NCT03541317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 Strategy: Augment with Facilitation
Description: In addition to first-line treatment (REP or REP + Coaching), schools will also receive support from a Facilitator who is a member of the study team and has expertise in CBT, implementation methods, and use of EBPs in schools will support SPs in strategic thinking and leadership skills to address organizational barriers.
Study NCT03541317 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stage 2 Strategy: No augmentation
Description: Schools will continue to receive their first-line treatment (REP or REP + Coaching); no additional support will be offered.
Study NCT04555434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Probiotics
Description: * Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose
Study NCT04555434 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics
Description: * Experimental group Main ingredients: P. pentosaceus KID7, L. lactis CKDB001 or L. helveticus CKDB001 (containing 9 × 10\^9 CFU / day)~* Control group Main ingredient: Crystalline cellulose
Study NCT02597829 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Certolizumab Pegol
Description: Subcutaneous Injection
Study NCT03747679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bosutinib capsules high flavour
Description: bosutinib capsules in high flavour
Study NCT04027751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tropisetron
Description: Investigators administrated intravenously Tropisetron 5mg before anesthesia induction
Study NCT04027751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Investigators administrated intravenously 0.9% saline solution as a placebo
Study NCT03190252 — intervention group
Intervention type: OTHER
Intervention: Exposure to ambient pressure of maximum 11 ATA
Description: Open sea diving to a maximum depth of 100 msw while breathing Trimix.
Study NCT03150706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.~Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.~Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study.
Study NCT00940719 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3
Description: Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
Study NCT00734968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin
Description: Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
Study NCT02843945 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Directional Brachytherapy Source Implant
Description: The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
Study NCT04370041 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dokimos Plus aortic valve
Description: Dokimos Plus aortic valve
Study NCT04296552 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary lowFODMAP intervention
Description: Twelve week strict lowFODMAP dietary intervention, involving restricted intake of fermentable carbohydrates (FODMAPs).
Study NCT03948373 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Description: In this group of patients (CPAP group) will be prescribed CPAP treatment at an optimal pressure. It will be performed a CPAP titration with an automatic or manual CPAP according to usual clinical practice.
Study NCT01992731 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Follitropine Bèta
Study NCT04302311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Holter monitoring
Description: Use of smart device application and technologies to assess for arrhythmias
Study NCT04302311 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Kardia/AliveCor monitoring
Description: Kardia/AliveCor monitoring
Study NCT03210909 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986231
Description: BMS-986231
Study NCT00883896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 1: Placebo SC administration every 2 weeks X 10 weeks.
Study NCT00883896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILV-094
Description: Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
Study NCT00883896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILV-094
Description: Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
Study NCT00883896 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part 2: Placebo SC administration every 2 weeks X 10 weeks
Study NCT00883896 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILV-094
Description: Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
Study NCT02419443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
Study NCT02419443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Control group
Study NCT04501380 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AEMCOLO (Rifamycin SV MMX)
Description: Participants will be issued a patient kit containing AEMCOLO (Rifamycin SV MMX) 194 mg tablets for the 1st or the 2nd treatment regimen in a random order.
Study NCT00517166 — intervention group
Intervention type: DEVICE
Intervention: CAT (Combat Arms Tourniquet)
Description: device
Study NCT02438787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
Study NCT02438787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 45 mg
Description: Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
Study NCT02438787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
Study NCT02438787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ustekinumab 90 mg
Description: Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
Study NCT02438787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
Study NCT02438787 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Golimumab 50 mg
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
Study NCT02438787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg
Description: Participants who meet EE criteria (less than \[\<\] 10 percent \[%\] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
Study NCT01062230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib (Velcade)
Description: Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.~Patients will undergo three 21-day cycles.
Study NCT00323934 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MGCD0103
Description: Oral dosage 2 times weekly.
Study NCT00142428 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
Study NCT01385839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hair transplantation
Description: Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
Study NCT01385839 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypodermic needle irritation
Description: In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
Study NCT04357431 — intervention group
Intervention type: OTHER
Intervention: self-administered questionnaire
Description: Data will be collected using Google online self-administered questionnaire disseminated in Arabic language
Study NCT02107716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lidocaine injection with bicarbonate
Description: bicarbonate added to change pH
Study NCT02107716 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lidocaine injection
Description: Lidocaine injection with pH unchanged
Study NCT00003524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT03249259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline alfoscerate
Description: Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
Study NCT03249259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Treatment duration is 6 months and can be extended to 12 months with participant's agreement.
Study NCT00439920 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-dose anthracycline
Study NCT04295629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Research on the effects of Ilioinguinal Nerve Block on Chronic Pain in Patients who undergo Inguinal Hernia with Spinal Anesthesia
Description: The patients underwent inguinal hernia operation randomly classified into two groups in the operating room as; Group I (n:30); spinal block (SA): All patients were given SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space. Times when the block reached T10 level were recorded.
Study NCT04295629 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ilioinguinal nerve block
Description: Group 2 (n:30); SA in sitting position and 3ml 0.5% hyperbaric bupivacaine was injected in sterile conditions with 25 G injection in L3-4, L4-5 subarachnoid space and as a ilioinguinal block (IHNB) 10 ml 5% bupivacaine was injected to patients with peripheric nerve block injection in the reanimation unit after the surgery.
Study NCT03466216 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AlphaMedix
Description: There is only a single treatment intervention.
Study NCT02513680 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Infrared Laser + Amber LED
Description: This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.